Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.53 |
| ▸ | PPARA | Q07869 | 3/20 | 0.53 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.46 |
| ▸ | ECE1 | P42892 | 5/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20214100 | 1.00 | PPARG (0.53) | PPARGPPARAPPARDMTNR1BSLC6A9 | |
| SCHEMBL820921 | 1.00 | PPARG (0.53) | PPARGPPARAPPARDMTNR1BSLC6A9 | |
| SCHEMBL6229546 | 1.00 | PPARG (0.53) | PPARGPPARAPPARDMTNR1BSLC6A9 | |
| SCHEMBL6207342 | 1.00 | PPARG (0.53) | PPARGPPARAPPARDMTNR1BSLC6A9 | |
| SCHEMBL821387 | 1.00 | PPARG (0.53) | PPARGPPARAPPARDMTNR1BSLC6A9 | |
| SCHEMBL20214136 | 1.00 | PPARG (0.53) | PPARGPPARAPPARDMTNR1BSLC6A9 | |
| SCHEMBL13355771 | 0.89 | MTNR1A (0.48) | PPARGPPARAPPARDMTNR1BMTNR1A | |
| SCHEMBL820653 | 0.89 | MTNR1A (0.48) | PPARGPPARAPPARDMTNR1BMTNR1A | |
| SCHEMBL821467 | 0.89 | MTNR1A (0.48) | PPARGPPARAPPARDMTNR1BMTNR1A | |
| SCHEMBL1400250 | 0.84 | PPARA (0.62) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3548023-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D Therapeutics, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018102358-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018102358-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| WO-2018102399-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20060084680-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-04-20 | — | — | US | disclosed |
| EP-1578715-A2 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | Bayer Pharmaceuticals Corporation (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050107392-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-05-19 | — | — | US | disclosed |
| US-20050075338-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-04-07 | — | — | US | disclosed |
| EP-1497271-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | Bayer Pharmaceuticals Corporation (US) | 2005-01-19 | — | — | EP | disclosed |
| US-6828335-B2 | Oxazole or thiazole-ethyl-oxy-indane acetic acid derivatives; useful for the treatment of diseases such as diabetes, obesity, hyperlipidemia and atherosclerosis | BAYER PHARMACEUTICALS CORPORATION | 2004-12-07 | — | — | US | disclosed |
| WO-2004058174-A2 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004011446-A1 | INDANE, DIHYDROBENZOFURAN, AND TETRAHYDRONAPHTHALENE CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20030216391-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER HEALTHCARE LLC | 2003-11-20 | — | — | US | disclosed |
| WO-2003089418-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107392-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents | GPR119, INSR, IRS1 | PPARG 280/4885PPARA 156/4885PPARD 467/4885 |
| US-20050075338-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | INSR, ACACA, IAPP | PPARG 578/4885PPARA 365/4885PPARD 978/4885 |
| US-20060084680-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | INSR, ACACA, IAPP | PPARG 578/4885PPARA 365/4885PPARD 978/4885 |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | CHRNA2, ACACA, CHAT | PPARG 988/4885PPARA 534/4885PPARD 1175/4885 |
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | CHAT, ACHE, CHRNA2 | PPARG 621/4885PPARA 516/4885PPARD 1188/4885 |
| US-20030216391-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | INSR, ACACA, IAPP | PPARG 578/4885PPARA 365/4885PPARD 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.